Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Market Advantage Of 'MR-Conditional' Device Labeling Fades

Executive Summary

Abbott Laboratories and Boston Scientific recently logged approvals that bring the firms closer to parity with Medtronic in being able to market their cardiac rhythm management devices as compatible with MRI scans. But CMS, the US Medicare agency, is currently considering a coverage policy that make so-called "MR-conditional" product labeling less significant.

You may also be interested in...

Major Trial Of Medtronic's ECG Belt Begins

The company announced the launch of a US randomized trial of its ECG Belt Research System, a tool to optimize cardiac resynchronization.

Medicare MRI Restrictions Removed For Cardiac Device Patients

The US Centers for Medicare and Medicaid Services followed through with a plan to expand its national coverage policy for MRI scans, removing contraindications and clinical-study requirements for patients with pacemakers, implantable cardioverter defibrillators and other cardiac rhythm devices.

Earnings Winners & Losers: ABMD, BSX, EW, ABT Pump Money Into Cardio; SYK, ZBH Innovate Ortho Surgery

Most of the major medical device companies have reported sales and earnings for the last three months of 2017 and the full year. Cardiovascular companies are succeeding with new technology while continuing to grow revenues from established technologies, especially in emerging markets. Orthopedic firms are looking to new technology, like surgery robots and neurostimulation, to differentiate themselves from the competition and improve profits.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts